ADMA Biologics, Inc. Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Confidential Portions denoted by [***] PLASMA SUPPLY AGREEMENT

Confidential Materials Omitted and Filed Separately with the

Securities and Exchange Commission

Confidential Portions denoted by [***]

THIS PLASMA SUPPLY AGREEMENT (“Agreement”) between Biotest Pharmaceuticals Corporation, a Delaware corporation, having a place of business at 0000 Xxxx xx Xxxxxxxx Xxxxxxxxx XX, Xxxx Xxxxx, Xxxxxxx 00000 (“BPC”) and ADMA Biologics, Inc., a Delaware corporation, having a place of business at 00 Xxxxxxxx Xxx, Xxxxxxxxxx, Xxx Xxxxxx 00000 (“ADMA”) shall be effective as of June 22, 2012 (the “Effective Date”). BPC and ADMA are each sometimes referred to herein individually as a “Party” or collectively as the “Parties.”

RECITALS

WHEREAS, ADMA desires to sell, and BPC desires to purchase certain quantities of normal source plasma (“Plasma”) to be used by BPC in the manufacturing of a Human Immune Globulin (“Product”), solely on the terms and conditions set forth in this Agreement;

PROVISIONS

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and with the intent to be legally bound hereby, ADMA and BPC agree as follows:

A.	PURCHASE AND SALE OF PLASMA

1. TERM OF AGREEMENT

. Unless terminated earlier as provided herein, the term of this Agreement shall continue until December 31, 2014 from the Effective Date (the “Initial Term”). After the Initial Term, this Agreement may be renewed on an annual basis upon the mutual consent of the Parties. Each Party agrees that it will endeavor, in good faith, to conclude any negotiations relating to such renewals [***] before the expiration of this Agreement

2. PRICE AND VOLUMES

YEAR	PRODUCT	VOLUME	PRICE
2012	Normal Source Plasma [***]	[***]	[***]
2012	Normal Source Plasma	[***]	[***]
2013	Normal Source Plasma	[***]	[***]
2014	Normal Source Plasma	[***]	[***]

- 1 -

a. The price of all purchases of Plasma under this Agreement [***]. Any additional required testing as specified by FDA (or foreign equivalent) or due to a change in BPC’s Specifications, will be billed to BPC at [***].

Beginning in 2014, the pricing for Plasma will be the price in effect as of December 31, 2013, per liter, [***]. [***] is defined as the [***].

b. BPC agrees to provide to ADMA a forecast, [***] of the Effective Date of this Agreement, for the desired 2012 quantities of Plasma, as defined in the table above. ADMA will confirm [***] the minimum quantities it will provide to BPC for 2012 (“2012 Plasma Minimum”). BPC will then issue a binding purchase order for the 2012 Plasma Minimum. [***] 2012 Plasma Minimum [***].

c. In addition, for 2013 and 2014, BPC agrees to provide to ADMA a forecast, [***] the start of the next calendar year of the agreement [***]. ADMA will confirm [***] the minimum quantities it will provide to BPC (“Annual Plasma Minimum”). BPC will then issue a binding purchase order for the Annual Plasma Minimum. [***] the volume as specified in the binding purchase order [***]of the current contract year of its [***].

3. PAYMENT TERM

Subject to Section C hereof, all Plasma shall be paid for [***]. Payments shall become delinquent [***]. Any undisputed payments not paid [***] after BPC receives notification from ADMA of said late payment shall accrue interest to be paid at the rate of [***]. Invoice to be issued [***]. All payments due hereunder to ADMA shall be sent to ADMA at the times set forth herein by wire transfer to such accounts as ADMA may designate to BPC.

Invoices to BPC will be directed to:

Biotest Pharmaceuticals Corporation

[***]

0000 Xxxx xx Xxxxxxxx Xxxxxxxxx XX

Xxxx Xxxxx, Xxxxxxx 00000

[***]

4. INSPECTION AND ACCEPTANCE.

a. BPC shall inspect each shipment of Plasma for conformity with the BPC’s specifications as set forth in Exhibit A (Specifications) [***] of the Plasma’s arrival at BPC’s facility. BPC shall promptly notify BPC in writing of its determination of any non-conformity of the Plasma with BPC Specifications (“Non-conformity Notice”).

b. If a Non-conformity Notice is received by ADMA, the Parties shall meet to determine whether such Plasma meets the BPC Specifications. If it is determined that the Plasma does not meet the BPC Specifications, ADMA shall [***], as promptly as possible, taking into account the time required to [***]. In the event the Parties fail to agree whether or not any given shipment of Plasma conforms with the BPC Specifications, then the matter will be promptly referred to an independent expert agreed in good faith by the Parties, whose decision shall be binding on the Parties. The cost of referral to the expert will be borne by [***].

- 2 -

c. For each shipment of Plasma delivered, ADMA shall provide BPC with a quality certificate and other industry standard documents required by regulatory authorities relating to the Plasma.

5. SHIPMENT TERMS. [***]. ADMA will invoice BPC for the Plasma at time of delivery to [***] and [***]. BPC will take ownership and bear all risk of loss upon [***].

B.	QUALITY OF PLASMA

All Plasma sold under this Agreement by ADMA to BPC shall meet BPC’s Specifications.

ADMA shall supply to BPC for the Initial Term, and any extensions thereof, Plasma to be derived from automated plasmapheresis procedures conducted at Center as specified in Exhibit B. ADMA warrants that the Center is FDA approved and IQPP certified.

Upon BPC’s application to the German Health Authority (“GHA”), ADMA shall use best efforts to take all necessary steps as soon as possible to become compliant with the GHA regulations and receive certification from the GHA.

ADMA and BPC shall execute a mutually agreeable Quality Agreement [***] of the Effective Date.

[***].

BPC shall have the right to conduct periodic inspections of ADMA’s centers and facilities dealing with the Plasma at times mutually agreeable to the parties. Such inspections shall be limited to matters directly related to this Agreement and shall be conducted in conformance with generally accepted industry practices. BPC will provide ADMA with not less than [***] prior to any of its inspections, unless mutually agreed otherwise by the parties. Upon receipt of BPC’s audit report, ADMA shall [***] to send a response to the appropriate BPC, outlining the corrective actions that ADMA will take at its expense, to correct the audit deficiencies. Further, ADMA agrees to provide BPC with copies of all written reports (including FDA 483’s) and correspondence between ADMA and any governmental agency regarding any such inspection or review of records [***] (i) receipt of any such report or correspondence from the governmental agency or (ii) the issuance or delivery of any response or correspondence by ADMA; provided, however, that in the event the report or correspondence relates to a serious problem that could affect the continuous supply, or quality of the Plasma, then ADMA agrees to use all reasonable efforts to notify BPC [***] of receipt of such report or correspondence and to provide BPC with a copy of such report or correspondence.

- 3 -

LIMITED WARRANTY ADMA represents and warrants to BPC that the Plasma has been collected and produced in accordance with BPC Specifications and BPC approved SOP’s. ADMA represents, warrants and agrees that any and all Plasma shall be collected, produced and delivered in accordance with all local, state and national laws, regulations and requirements. BPC shall have all rights and remedies available to it under this Agreement and shall not be obligated to buy or pay for any Plasma which does not, in all respects, comply with the BPC Specifications and applicable law, rules and regulations and as otherwise required by this Agreement, provided BPC must submit notification of rejection [***] of receipt of such Plasma. This warranty shall be further limited by the expiry of the Plasma and shall not apply to any expired Plasma.

D.	MISCELLANEOUS

1. CONFIDENTIALITY.

a. The Parties agree to maintain the confidentiality of the contents of this Agreement and the dealings between the Parties with the same degree of care as they use to protect their own proprietary, confidential or trade secret information. The Parties shall not disclose to any third party any confidential information received from the other hereunder without that other Party’s prior written consent and shall use it only for the purpose of this Agreement. The Parties agree to hold the name and location of any and all testing labs and facilities as well as names of key personnel at the testing labs as confidential information. Said obligation of secrecy shall not apply to any information which (a) was in the public domain at the time of its disclosure or thereafter becomes part of the public domain by publication or otherwise subsequent to the time of disclosure under this Agreement through no fault of the receiving party; or (b) was known to the receiving party or in its possession prior to or at the time of disclosure as shown by written records; or (c) is independently developed by the receiving party without use of the other Party’s confidential information as shown by written documentation; or (d) is disclosed with the written approval of the disclosing party; or (e) is rightfully furnished to the receiving party by a third party having the authority to disclose such confidential information without restrictions; or (f) is disclosed by law or regulation or in response to a valid order of a court or other governmental body, or is required for registration of a product by competent authorities, but only to the extent of and for the purpose of such law, regulation, order or registration, and only if the receiving party first notifies the disclosing party of the required disclosure and permits the disclosing party, at its expense, to seek an appropriate legal remedy to maintain the information in secret.

b. The above obligations shall survive the termination of this Agreement and shall continue with respect to donor information without limit of time and in respect of other confidential information for [***].

2. RELATIONSHIP OF THE PARTIESThe relationship between ADMA and BPC during the term of this Agreement, including extensions and renewals, is strictly that of buyer and seller. Neither Party is in any way the legal representative, agent, joint venturer nor partner of the other for any purpose whatsoever nor neither has any control or authority whatsoever to bind the other Party or any other person with respect to the other Party.

- 4 -

3. INDEMNIFICATION ADMA and BPC hereby indemnify and agree to hold harmless each other and their respective affiliates, agents, employees, officers and directors, from and against any and all third party claims, losses, liabilities, damages, reasonable attorneys’ fees, costs and expenses (hereinafter “Claims”) which may be sustained by and/or claimed against the other Party by virtue of their negligent acts, negligent omissions or the negligent handling or furnishing of materials or performance of services rendered by the other Party, the willful misconduct by the other Party or its officers, employees or agents or any representation, warranty or agreement contained in this Agreement being breached, untrue or materially misleading, by omission or otherwise. Said indemnification will be capped at the dollar value of Plasma purchased in the year in which the relevant claim arises. The indemnifying party’s liability shall be reduced to the extent any such Claims arise as a result of the indemnified party’s own conduct or negligence. To the extent Plasma is being used to manufacture Product to be used in research or for commercial purposes, BPC specifically shall indemnify and hold harmless ADMA, its affiliates, directors, officers, agents and employees, from any and all liability, loss or damages, including reasonable attorneys’ fees they may suffer as the result of claims, demands, costs or judgments against them caused or contributed to by the Product or any procedure required by the research protocol or related to the commercial sale of such product, if such liability, loss or damages are not directly caused or contributed to by such Plasma.

4. LIMITATION OF LIABILITY IN NO EVENT WILL EITHER PARTY HAVE ANY LIABILITY FOR ANY LOSS OF INCOME, PROFIT, INTEREST OR SAVINGS BY THE OTHER PARTY OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR SPECIAL DAMAGES SUFFERED BY THE OTHER PARTY, ARISING FROM OR RELATED TO THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, THE SALE OR USE OF ANY PLASMA, REGARDLESS OF THE FORM OF ACTION, AND WHETHER IN CONTRACT, INDEMNITY, WARRANTY OR TORT INCLUDING WITHOUT LIMITATION STRICT LIABILITY AND NEGLIGENCE OR ANY OTHER LEGAL OR EQUITABLE GROUNDS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES. THIS LIMITATION WILL NOT APPLY TO ANY LIABILITY FOR DAMAGES THAT MAY RESULT FROM THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF A PARTY.

The Party from whom indemnity is sought shall be entitled at its option to defend or control the defense and/or settlement of any such claim.

Each Party shall notify the other of any claim or potential claim or liability as soon as it becomes aware that such claim, potential claim or liability has arisen and shall provide to the other, all-reasonable assistance in respect thereof.

5. INSURANCE ADMA and BPC shall each be required to maintain general and product liability insurance in an amount of [***]. Before commencing any work hereunder, the Parties shall furnish certificates evidencing the insurance required by this Section. The Parties shall give each other [***] days advance written notice in the event the insurance required by this Section is materially modified, or cancelled or otherwise terminated for any reason.

E.	TERMINATION

1. In addition to any other remedy it may have, either Party shall have the right to terminate this Agreement [***] of written notice thereof.

2. Upon giving the appropriate written notice, either Party may terminate this Agreement upon the occurrence of the following event: a proceeding under any bankruptcy, reorganization, arrangement of debts, insolvency or receivership law is filed by or against the other Party, and is not dismissed or stayed [***], or a receiver or trustee is appointed for all or a substantial portion of the assets of the other Party, or the other Party makes an assignment for the benefit of its creditors or becomes insolvent.

- 5 -

3. Upon termination of this Agreement, BPC must pay for any Plasma already delivered to BPC. Notwithstanding anything to the contrary set forth herein, the Parties’ obligations under this Agreement in Sections B, C, D, E and H shall survive the termination of this Agreement to the extent necessary to give effect to their reasonable intentions.

F.	FORCE MAJEURE

1. Neither Party shall be liable for non-performance caused by strikes, fires, explosions, Acts of God, riots, civil or international war, acts of terrorism, an unexpected downturn in the acceptable donor population adversely affecting the industry as a whole, inability to obtain Plasma because of Force Majeure at the producing location, or any other similar or dissimilar cause beyond the reasonable control of either Party which renders the performance of a Party’s obligations so difficult or costly as to make such performance commercially unreasonable. The affected Party shall immediately inform the other of such occurrences and the termination thereof.

2. Upon giving notice to the other Party, a Party affected by an event of Force Majeure shall be released without any liability on its part from the performance of its obligations under this Agreement, except for the obligation to pay any amounts due and owing hereunder, but only to the extent and only for the period that its performance of such obligations is prevented by the event of Force Majeure. Such notice shall include a description of the nature of the event of Force Majeure, and its cause and possible consequences. The Party claiming Force Majeure shall promptly notify the other Party of the termination of such event.

3. Should the period of Force Majeure continue for more [***], then the Party not suffering the Force Majeure event may terminate this Agreement upon giving written notice to the other Party.

G.	REMEDIES EXCLUSIVE

1. The rights and remedies available to ADMA and BPC under this Agreement among the Parties are exclusive.

2. [***].

H. DISCLOSURES AND PUBLICITY. Neither ADMA, on the one hand, nor BPC, on the other hand, shall, without the approval of the other, make any press release or other public announcement concerning the transactions contemplated by this Agreement, except as and to the extent that any such Party shall be so obligated by law, in which case the other Party shall be advised and the Parties shall use their commercially reasonable efforts to cause a mutually agreeable release or announcement to be issued; provided, however, that the foregoing shall not preclude communications or disclosures necessary to implement the provisions of this Agreement or to comply with the accounting and disclosure obligations of the Securities and Exchange Commission (“SEC”) or the rules of any stock exchange or NASDAQ. Notwithstanding any contrary term contained in the confidentiality provisions of this Agreement, to the extent that either Party determines that it or the other Party is required to file or register this Agreement, a summary thereof, or a notification thereof, and/or descriptions related thereto, to comply with the requirements of an applicable stock exchange, SEC regulation, or any Governmental Authority, including the SEC, or to enable either Party to obtain debt or equity financing, such Party shall use its best efforts to provide the maximum amount of advance written notice of any such required disclosure to the other Party, to the extent practicable, with a minimum advance notice [***]. Prior to making any such filing, registration or notification, the Parties shall consult with respect thereto regarding confidentiality. The Parties shall cooperate, each at its own expense, in such filing, registration or notification, including such confidential treatment request, and shall execute all documents reasonably required in connection therewith.

- 6 -

I. ASSIGNMENT. Neither Party shall assign this Agreement or any of its rights or obligations hereunder without the express written consent of the other Party, except as hereinafter provided. Any such consent shall not be unreasonably withheld. With notice to the other Party, either Party without the other Party’s consent may assign this Agreement to (i) its affiliate, or (ii) a successor to all or substantially all of the assets relating to the business of that Party which is involved in the fulfillment of its obligations under this Agreement, which shall expressly assume in writing the performance of all of the terms and conditions of this Agreement then to be performed by such successor as if it were named herein as a Party.

J. NOTICES All notices, demands, requests, consents or approvals required under this Agreement must be in writing and delivered personally to the Party or sent by overnight courier service or facsimile, addressed to such Party as set forth below (or to such other address or facsimile number as such Party may hereafter specify for the purpose by notice to the other Party hereto):

To BPC:

[***]

Biotest Pharmaceuticals Corporation

0000 Xxxx xx Xxxxxxxx Xxxxxxxxx XX

Xxxx Xxxxx, XX 00000

[***]

With a copy to:

[***]

Biotest Pharmaceuticals Corporation

0000 Xxxx xx Xxxxxxxx Xxxxxxxxx XX

Xxxx Xxxxx, XX 00000

[***]

To ADMA:

Xxxx Xxxxxxxx

Chief Executive Officer

ADMA Biologics, Inc.

00 Xxxxxxxx Xxx

Xxxxxxxxxx, XX 00000

Fax: 000-000-0000

With a copy to:

General Counsel

ADMA Biologics, Inc.

00 Xxxxxxxx Xxx

Xxxxxxxxxx, XX 00000

All notices, requests, consents and other communications hereunder shall be deemed to have been properly given (a) if by hand, at the time of the delivery thereof to the receiving party at the address of such Party set forth above, (b) if made by facsimile transmission, at the time that receipt thereof has been acknowledged by electronic confirmation or otherwise, (c) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (d) if sent by registered or certified mail, on the fifth business day following the day such mailing is made.

- 7 -

K. INTEGRATION; EFFECT OF AMENDMENT This Agreement, including all attachments, schedules or other agreements specifically incorporated by reference, constitute the entire agreement among the Parties with respect to the subject matter of this Agreement and supersede any and all other prior written or oral agreements, understandings, negotiations or discussions among the Parties with respect to the subject matter of this Agreement. This Agreement may not be modified or amended in any respect except by an instrument in writing signed by both of the Parties.

L. CHOICE OF LAW This Agreement shall be governed by, and construed under laws of the State of Delaware, without regard to its conflict of laws principles.

M. REPRESENTATIONS AND WARRANTIES Each party hereto hereby represents and warrants to the other as follows: (i) each party hereto has all requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby, (ii) the execution and delivery of this Agreement and the consummation by such party of the transactions contemplated hereby have been duly authorized by all necessary action on the part of such party, (iii) this Agreement has been duly and validly executed and delivered by such party and constitutes the valid and binding obligation of such party, enforceable against such party in accordance with its terms and (iv) the execution and delivery of this Agreement and the consummation by such party of the transactions contemplated hereby does not and will not (a) require the consent of or registration with, any court, federal state, local or foreign governmental or regulatory body, or (b) constitute a default (with or without notice or lapse of time, or both) under or conflict with any contract, agreement or order to which such party is a party or by which such party or any of its properties or assets is subject or bound.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement by their duly authorized officers as of the day and year first written above.

ADMA Biologics, Inc. Biotest Pharmaceuticals Corporation

By: /s/ Xxxx Xxxxxxxx		By: /s/ Xxxxxx Xxxxxx

Name: Xxxx Xxxxxxxx		Name: Xxxxxx Xxxxxx

Title: President & CEO		Title: Chief Executive Officer

Date: June 22, 2012		Date: June 22, 2012

- 8 -

EXHIBIT A

SPECIFICATIONS

[Biotest Logo]

BIOTEST PHARMACEUTICALS CORPORATION

SOURCE PLASMA SPECIFICATIONS

[***]

A. ORIGIN OF PLASMA

Source Plasma must be collected from donors at USA—FDA licensed plasma center(s) and in accordance to all applicable laws and any relevant FDA Memoranda and Guidance documents.

If applicable, Source Plasma must be collected in accordance to current applicable EU regulations and the European Pharmacopoeia Monograph for “Human Plasma for Fractionation”

Plasma centers must be IQPP certified and adhere to PPTA voluntary standards. Source Plasma must be from plasma centers in compliance with PPTA IQPP Viral Marker Standards.

Source Plasma must be processed and stored according to All Applicable laws.

Copies of FDA registrations and European certificates (if applicable) shall be provided for each plasma center and testing laboratory. Updates to these documents shall be provided on an annual basis.

B. SELECTION AND EXCLUSION CRITERIA FOR DONORS AND PLASMA DONATIONS

The donor/donation selection shall be in accordance with all applicable laws and any relevant FDA guidelines; the current EU regulations (if applicable) and any relevant technical annexes and directives.

The donor eligibility criteria shall comply with the current FDA regulations and with applicable EU directives.

Acceptable plasma shall be only from Qualified Donors as defined by IQPP standards.

C. TESTING SPECIFICATIONS

Serology tests on individual units shall be in accordance with FDA requirements and performed with FDA-licensed test kits. Each unit shall be tested and found negative for the following:

[***]

Nucleic Acid Amplification tests (NAT) to be performed in accordance to FDA requirements (mini pools) and found negative for:

[***]

BPC Source Plasma Specifications Rev 03 July 12

page 1 of 7

Additional NAT tests to be performed in accordance to established USA and European guidelines:

[***]

Each donor must be tested and found negative in accordance to USA and European requirements for:

[***]

Any additional tests or modifications of existing tests shall be implemented as soon as they are required by the FDA and/or the European Pharmacopoeia monograph.

A list of all current test kits or methods shall be submitted to BPC, and updated in the event a test or method is changed.

D. PLASMA COLLECTION AND PROCESSING PROCEDURES

Source Plasma collection in bottles In accordance to FDA and European requirements (If applicable) current at the time of donation.

Procedures must be maintained and followed to ensure all donations are traceable to the individual donors.

Each Source Plasma bottle will be labeled with at least the following information:

Supplier name and license number

Plasma Type

Unit identification will be by means of bar-coded [***]

Volume

Anticoagulant composition

Storage temperature

Expiration date

Plasma bottle lot number (on bottle)

Source Plasma must be frozen by cooling rapidly within 24 hours of collection in validated freezers to ensure that a temperature of -25°C or colder is reached at the core of each plasma unit within 12 hours of placing in the freezer.

Source Plasma collected in non-EU approved plasma centers must be frozen at -20°C or colder immediately upon collection in accordance to FDA requirements.

BPC Source Plasma Specifications Rev 03 July 12

page 2 of 7

Plasma units that fall into one of the following categories are unacceptable for shipment to BPC:

Units with reactive or positive viral marker test results; Prior or subsequent units from donors that have been found to be reactive/positive for required testing

Hemolyzed or lipemic units

Units with frozen plasma on the outside of the container

Broken or contaminated units

Untested or units with Incomplete testing

Applicant/Orphan units

Units having errors that breach traceability such as units that cannot be traced back to an individual donor.

E. PLASMA STORAGE AND TRANSPORT REQUIREMENTS

Source Plasma must be stored and transported at -20°C or colder. All storage and transportation temperatures must be recorded and documented.

Temperature deviations during storage or shipment must be reported to BPC prior to shipment of the plasma. Salvaged Plasma as defined under 21 CFR is not acceptable to BPC.

[***]

Each packing case will be labeled at least with the following information:

Supplier name and license number

Plasma Type

Shipment ID #

Bar-coded Case number [***]

F. LOOKBACK AND POST-DONATION PROCEDURES

Plasma Supplier must have a Lookback and Notification procedure In place to report information that impacts the safety of Source Plasma shipped to BPC. This procedure must be compliant with FDA, State, EU (when applicable) and PPTA requirements.

Plasma Supplier must notify BPC in writing within three (3) business days of discovery of any of the following events:

Receipt of reactive test results from a donor from whom prior or subsequent units have been shipped to BPC. Confirmatory/supplemental results must be reported within twenty-one (21) calendar days of the bleed date of the reactive unit.

Receipt of Post Donation Information (e.g. tattoo, body piercing, high risk behavior) from a donor from whom prior or subsequent units have been [***]

Lookback reports and Post-Donation information must be forwarded to BPC electronically to the attention of:

[***]

Atten: [***]

Phone: [***]

BPC Source Plasma Specifications Rev 03 July 12

page 3 of 7

G. EPIDEMIOLOGICAL DATA REPORTS

Each plasma center must comply with PPTA IQPP Viral Marker Standards and EMEA data (if applicable) reporting requirements. Reports must be provided to BPC annually or more frequently upon request.

H. REQUIRED SHIPMENT DOCUMENTATION

Each shipment of Plasma must have the following shipment documentation and electronic information associated with it.

Xxxx of Lading (copy)

Certificate of Quality [***]

Shipping Report Summary

Shipment Report Detail

Plasma Packing and Test Report Forms

E-File [***]

Temperature Exposure Form/Statement [***]

The Xxxx of Lading shall include the following information:

Unique shipment number

Xxxx of Lading #

Shipment date

Collecting facility’s name and address

Plasma type

Total volume of shipment

Total number of units in the shipment

Total number of cases in the shipment

The Shipping Report Summary shall include the following information:

Shipment number

Collecting facllity’s name and address

License #

Plasma type

Cases, units and volume

Total cases, units and volume of shipment

Earliest and latest bleed date within the shipment

Temperature of plasma freezer at time of shipment & signature

Shipment date & time

Xxxx of Lading number

The Shipping Report Detail shall include the following Information:

Shipment number

Shipment date

Collecting facility’s name and address

License number

Plasma type

Units and volume by case

Total cases, units and volume of shipment

BPC Source Plasma Specifications Rev 03 July 12

page 4 of 7

The Plasma Packing and Test Report shall include the following information:

Shipment number

Plasma type

Case number [***]

Collecting facility’s name and address

Donation date

Donor number [***]

Unit number [***]

Volume

Test results

Total units and volume for each case

Signature and date of reviewer

The originals of this documentation are to be delivered electronically to the attention of:

[***]

BPC Source Plasma Specifications Rev 03 July 12

page 5 of 7

[***]

BPC Source Plasma Specifications Rev 03 July 12

page 6 of 7

[***]

BPC Source Plasma Specifications Rev 03 July 12

page 7 of 7

[***]

- 8 -

[***]

- 9 -

[***]

- 10 -

[***]

- 11 -

[***]

- 12 -

[***]

- 13 -

[***]

- 14 -

[***]

- 15 -

[***]

- 16 -

EXHIBIT B

ADMA PLASMA CENTERS

ADMA BioCenters Georgia Inc

0000 Xxxxx Xxxxxx Xxxxxxxxx

Xxxxx 000

Xxxxxxxx, XX 00000

Document Metadata

Table of Contents

ADMA Biologics, Inc. Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Confidential Portions denoted by [***] PLASMA SUPPLY AGREEMENT

Document Metadata